{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:10:42Z","timestamp":1780636242504,"version":"3.54.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ad.2024.10.071","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T09:27:29Z","timestamp":1744104449000},"page":"807-814","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Unraveling the Link Between Bullous Pemphigoid and Neurological Disease: A Single-center Study of 257 Patients"],"prefix":"10.1016","volume":"116","author":[{"given":"L.M.","family":"Nieto-Benito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Su\u00e1rez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2024.10.071_bib0155","first-page":"305","article-title":"Bullous pemphigoid: Italian guidelines adapted from the EDF\/EADV guidelines","volume":"153","author":"Cozzani","year":"2018","journal-title":"G Ital Dermatol Venereol"},{"key":"10.1016\/j.ad.2024.10.071_bib0160","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/bjd.19022","article-title":"Incidence, prevalence and mortality of bullous pemphigoid in England 1998\u20132017: a population-based cohort study","volume":"184","author":"Persson","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2024.10.071_bib0165","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3389\/fmed.2018.00220","article-title":"The growing incidence of bullous pemphigoid: overview and potential explanations","volume":"5","author":"Kridin","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ad.2024.10.071_bib0170","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jamadermatol.2020.1587","article-title":"Association between medication use and bullous pemphigoid: a systematic review and meta-analysis","volume":"156","author":"Liu","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ad.2024.10.071_bib0175","doi-asserted-by":"crossref","first-page":"662","DOI":"10.2174\/1871530318666180731115226","article-title":"Bullous pemphigoid and neurologic diseases: toward a specific serologic profile?","volume":"18","author":"Petrera","year":"2018","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"10.1016\/j.ad.2024.10.071_bib0180","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000315393","article-title":"Sera of elderly bullous pemphigoid patients with associated neurological diseases recognize bullous pemphigoid antigens in the human brain","volume":"57","author":"Chen","year":"2011","journal-title":"Gerontology"},{"key":"10.1016\/j.ad.2024.10.071_bib0185","doi-asserted-by":"crossref","first-page":"e551","DOI":"10.1016\/S2468-2667(20)30190-0","article-title":"The burden of neurological diseases in Europe: an analysis for the Global Burden of Disease Study 2017","volume":"5","author":"Deuschl","year":"2020","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.ad.2024.10.071_bib0190","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jaad.2019.02.017","article-title":"Drugs used for neurologic and psychiatric conditions increase the risk for bullous pemphigoid: a case\u2013control study","volume":"81","author":"Varpuluoma","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2024.10.071_bib0195","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/2013.jamadermatol.376","article-title":"The associations between bullous pemphigoid and drug use: a UK case\u2013control study","volume":"149","author":"Lloyd-Lavery","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ad.2024.10.071_bib0200","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1111\/jdv.13660","article-title":"Bullous pemphigoid and its association with neurological diseases: a systematic review and meta-analysis","volume":"30","author":"Lai","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2024.10.071_bib0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2019.01.034","article-title":"Demographics and autoantibody profiles of pemphigoid patients with underlying neurologic diseases","volume":"139","author":"Messingham","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ad.2024.10.071_bib0210","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/jdv.15444","article-title":"Neurological disorders are associated with bullous pemphigoid","volume":"33","author":"Papakonstantinou","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2024.10.071_bib0215","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00403-017-1772-x","article-title":"Mortality in bullous pemphigoid and prognostic factors in 1st and 3rd year of follow-up in specialized centre in Poland","volume":"309","author":"Kalinska-Bienias","year":"2017","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.ad.2024.10.071_bib0220","doi-asserted-by":"crossref","first-page":"637","DOI":"10.17219\/acem\/90922","article-title":"The association between neurological diseases, malignancies and cardiovascular comorbidities among patients with bullous pemphigoid: case\u2013control study in a specialized Polish center","volume":"28","author":"Kali\u0144ska-Bienias","year":"2019","journal-title":"Adv Clin Exp Med"},{"key":"10.1016\/j.ad.2024.10.071_bib0225","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1111\/jdv.17304","article-title":"Coexistence of bullous pemphigoid with neuropsychiatric comorbidities is associated with anti-BP230 seropositivity","volume":"35","author":"St\u00e4nder","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2024.10.071_bib0230","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3389\/fimmu.2019.00236","article-title":"Anti-BP180 autoantibodies are present in stroke and recognize human cutaneous BP180 and BP180-NC16A","volume":"10","author":"Wang","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.ad.2024.10.071_bib0235","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/jdv.18220","article-title":"Updated S2K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)","volume":"36","author":"Borradori","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2024.10.071_bib0240","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1111\/jdv.17465","article-title":"The burden of neurological comorbidities in six autoimmune bullous diseases: a population-based study","volume":"35","author":"Kridin","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2024.10.071_bib0245","doi-asserted-by":"crossref","first-page":"37125","DOI":"10.1038\/srep37125","article-title":"Psychiatric and neurological disorders are associated with bullous pemphigoid \u2013 a nationwide Finnish Care Register study","volume":"6","author":"F\u00f6rsti","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.ad.2024.10.071_bib0250","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/jid.2010.357","article-title":"The relationship between neurological disease and bullous pemphigoid: a population-based case\u2013control study","volume":"131","author":"Langan","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ad.2024.10.071_bib0255","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1016\/j.jaad.2019.03.091","article-title":"Bullous pemphigoid and neuropsychiatric medications: an influence of drugs or of underlying conditions?","volume":"88","author":"Kridin","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2024.10.071_bib0260","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jaad.2019.04.025","article-title":"Reply to: Comment on \u201cBullous pemphigoid and neuropsychiatric medications: an influence of drugs or of underlying conditions?\u201d","volume":"88","author":"Varpuluoma","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2024.10.071_bib0265","doi-asserted-by":"crossref","first-page":"602","DOI":"10.2340\/00015555-3166","article-title":"Gliptin-associated bullous pemphigoid and the expression of dipeptidyl peptidase-4\/CD26 in bullous pemphigoid","volume":"99","author":"Lindgren","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ad.2024.10.071_bib0270","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1111\/jdv.12995","article-title":"Neurological disorders in patients with bullous pemphigoid: clinical and experimental investigations","volume":"29","author":"Gambichler","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2024.10.071_bib0275","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v102.2938","article-title":"Skin eosinophil counts in bullous pemphigoid as a prognostic factor for disease severity and treatment response","volume":"103","author":"Baum","year":"2023","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ad.2024.10.071_bib0280","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/1346-8138.16654","article-title":"What's new in the pathogenesis and triggering factors of bullous pemphigoid","volume":"50","author":"Ujiie","year":"2023","journal-title":"J Dermatol"},{"key":"10.1016\/j.ad.2024.10.071_bib0285","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.1111\/ajd.13547","article-title":"Tissue eosinophil levels as a marker of disease severity in bullous pemphigoid","volume":"62","author":"Gore Karaali","year":"2021","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.ad.2024.10.071_bib0290","doi-asserted-by":"crossref","first-page":"544","DOI":"10.5021\/ad.2018.30.5.544","article-title":"Circulating eosinophil and neutrophil counts correlate with disease severity in bullous pemphigoid","volume":"30","author":"Park","year":"2018","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.ad.2024.10.071_bib0295","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/bjd.16679","article-title":"Peripheral eosinophilia in bullous pemphigoid: prevalence and influence on the clinical manifestation","volume":"179","author":"Kridin","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2024.10.071_bib0300","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s12026-018-9028-1","article-title":"Biological predictors shared by dementia and bullous pemphigoid patients point out a cross-antigenicity between BP180\/BP230 brain and skin isoforms","volume":"66","author":"Julio","year":"2018","journal-title":"Immunol Res"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731025002340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731025002340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T09:12:14Z","timestamp":1756717934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731025002340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0001731025002340"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2024.10.071","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unraveling the Link Between Bullous Pemphigoid and Neurological Disease: A Single-center Study of 257 Patients","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2024.10.071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}